Moderna Shares Jump 8% After Company Flags Early Hantavirus Vaccine Work

MT Newswires Live05-11 17:53

Moderna (MRNA) shares rose over 7% in Monday's premarket after the company, as per Bloomberg, said it has been working on early-stage vaccines targeting hantaviruses.

The vaccine maker said its research is still at an early stage and had begun before recent infections were reported aboard the Dutch-flagged Hondius, according to Bloomberg. The work is being carried out with the U.S. Army Medical Research Institute of Infectious Diseases and the Korea University College of Medicine, the report said.

Moderna said its broader strategy includes preparing for emerging health threats using its mRNA platform, which can be adapted more quickly than conventional vaccine technologies, the report added.

Price: 58.43, Change: +4.08, Percent Change: +7.51

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment